Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Scrip   
Gilead's quad pill for HIV non-inferior to Atripla in Phase II
13 January 2010
Asher Mullard

Gilead Sciences' new "quad" pill combination drug for HIV – which combines its investigational integrase inhibitor elvitegravir, emtricitabine, tenofovir disoproxil fumarate and its new experimental boosting agent GS-9350 – is non-inferior to its three drug standard combination Atripla...



Please Login to read the full article.
 
Not a subscriber? Request a FREE Trial Subscribe to Scrip
RELATED CONTENT
NEWS Scrip News Other Informa News
ANALYSIS Scrip Analysis
COMMENT Scrip Comment Other Informa Comment
FEATURES Scrip Features Other Informa Features
SCIENCE
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm